Home / Catalogue/ Growth recovery/ IGF-1 LR3

Growth recoveryIn StockSubQ injection

IGF-1 LR3

Polypeptide · Long R3 IGF-1 analogue · 83 amino acids

Half-life

~20-30h

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

2–4 weeks

Refrigerate at 2-8C

Known For

Long-acting insulin-like growth factor. Directly stimulates muscle growth and cell proliferation. More potent than standard IGF-1 (longer half-life). Promotes hyperplasia (new muscle cell creation) not just hypertrophy.

Mechanism of Action

Modified IGF-1 — downstream effector of GH. Directly drives muscle growth, cell proliferation, protein synthesis. Bypasses GH entirely.

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

No brand for LR3 variant Related: Increlex® (mecasermin/rIGF-1) Increlex is natural IGF-1, not LR3

Typical Research Dosage

20-80mcg/day SubQ or IM (bilateral into target muscles). Most use 40-60mcg/day. Cycle 4-6 weeks on, 4-6 off.

Vial Duration Guide

1mg vial at 50mcg/day = 20 days. 0.1mg vial = 2 days.

Recommended Vial Size

★ 1mg vials At 50mcg/day, 1mg = 20 days ✓. 0.1mg = 2 days (impractical). IGF-1 is FRAGILE (2-4 wk shelf life). 1mg is the only practical choice.

Time to Effects

EARLY: 1-2 weeks FULL: 4-6 weeks Week 1: Pumps during training, potential hypoglycaemia (have glucose source ready). Muscle fullness. Week 2-4: Noticeable muscle growth and recovery. Localised growth in injected muscle groups. Week 4-6: Significant body composition changes. New muscle cell creation (hyperplasia) — permanent gains. ⚠️ Cycle 4-6 weeks on, 4-6 off. Effects are relatively fast due to direct growth factor activity. Monitor blood glucose closely.

Contraindications & Do Not Combine

⚠️ CONTRAINDICATED in any personal or family history of cancer — IGF-1 is a potent growth factor strongly associated with cancer risk • Caution combining with exogenous HGH (compounded growth factor load, insulin resistance) • Do NOT use on days you inject MGF/PEG-MGF (alternate — MGF for repair days, IGF-1 for growth days) • ⚠️ Monitor blood glucose — can cause hypoglycaemia

Common Side Effects

Hypoglycaemia (SIGNIFICANT — 15-25%), joint pain, headache, jaw/hand growth (chronic use), organ growth

Drug Interactions

Insulin (synergistic hypoglycaemia risk — DANGEROUS), anti-diabetics, other growth factors

Reversibility

⚠️ Suppresses natural GH/IGF-1 production via negative feedback. Recovery: weeks to months.

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Francis et al. (1992) J Mol Endocrinol 8:213-23 — LR3 characterization • Pharmaceutically, mecasermin (Increlex) is FDA-approved rIGF-1 for severe GHD • LR3 variant is research-only — longer half-life than native IGF-1 • NOT FDA APPROVED (LR3 specifically) • ⚠️ Hypoglycemia risk well documented

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Reconstituted: 2-8°C, 14-21 days. Very fragile — avoid shaking.

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	2–4 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

IGF-1 LR3 discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$45.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~20-30 hours (LR3 modification extends half-life vs native IGF-1 at ~12 min)
Delivery	SubQ injection
Typical dose	20-80mcg/day
Storage (lyoph.)	2–8°C
Storage (recon.)	2–4 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	Suppresses endogenous IGF-1
WADA	Prohibited (S2)
FDA status	Category 2 (2023)